Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVERIC trial of CardiolRx after IL-1 blocker cessation in recurrent pericarditis
2024-517688-21-00Phase 3Completed
- Sponsor
- Cardiol Therapeutics Inc.
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in recurrent pericarditis comparing CardiolRx with Placebo (2 arms). Primary endpoints: Proportion free from recurrent pericarditis through Week 24, Protocol definition of recurrent pericarditis event and 1 more. Started Apr 2025; status: completed.
02
Drugs
cannabidiol
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on 2024-517688-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517688-21-00.